PFIZER has confirmed it will extend its Corex brand range in India to encompass a new range of respiratory products, following the withdrawal of its popular Corex cough syrup earlier this year.
Corex, a combination of codeine and chlopheniramine maleate, was one of 344 fixed dose products banned by regulators in India in Mar, with officials saying they had "no therapeutic justification".
Pfizer said it stood by the safety and efficacy of the Corex cough syrup formulation, but said it would discontinue it and instead launch a "series of products as line extensions under the Corex brand name" starting this month.
The announcement came as the Delhi High Court yesterday set aside the earlier decision banning the fixed dose combination medicines, impacting about 6,000 brands.
The ruling led to legal challenges from scores of manufacturers including Procter & Gamble, Sanofi, Dr Reddy's and Abbott who argued their products had been on the market for decades.
The above article was sent to subscribers in Pharmacy Daily's issue from 02 Dec 16
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 02 Dec 16
